Alkermes plc (ALKS)

Etorro trading 970x250
Alkermes plc (ALKS) Logo

About Alkermes plc

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Address: Connaught House, Dublin, Ireland, 4

Alkermes plc News and around…

Latest news about Alkermes plc (ALKS) common stock and company :

Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder
18 Oct, 2021 Yahoo! Finance

Alkermes plc (Nasdaq: ALKS) today announced that LYBALVI® (olanzapine and samidorphan) is now available by prescription in the United States (U.S.) for the treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes as monotherapy or an adjunct to lithium or valproate. LYBALVI is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agen

3 Mid-Cap Stocks With Large-Cap Potential
15 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Large-cap stocks hog the spotlight, but mid-cap stocks have higher growth potential and can help diversify your portfolio. The post 3 Mid-Cap Stocks With Large-Cap Potential appeared first on InvestorPlace. 5 Triple A-Rated Stocks to Buy for October

Top Ranked Momentum Stocks to Buy for October 13th
13 Oct, 2021 Yahoo! Finance

ALKS, BP, and E made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 13, 2021.

2 Supercharged Stocks Near 52-Week Highs Despite the Market Pullback
13 Oct, 2021 FinancialContent

Are they stocks to buy near the highs?

Hedge Funds Have Never Been This Bullish On Alkermes Plc (ALKS)
12 Oct, 2021 Yahoo! Finance

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?
06 Oct, 2021 Yahoo! Finance

Marc Lichtenfeld, an expert in biotech and income stocks, notes that a lot of Wall Street money moves into companies that issue positive Phase 2 clinical trial data.

Alkermes Stock Composite Rating Rises To Near-Perfect 96 As It Posts Erratic But Huge Sales Gains
05 Oct, 2021 Yahoo! Finance

Top-ranked drugmaker Alkermes saw its IBD SmartSelect Composite Rating jump to 96 Tuesday, up from 94 the day before. The new rating shows Alkermes stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. Among other key ratings, Alkermes also has a 94 Relative Strength Rating, which gauges a stock's price strength against all others.

Recent 4.9% pullback isn't enough to hurt long-term Alkermes (NASDAQ:ALKS) shareholders, they're still up 88% over 1 year
05 Oct, 2021 Yahoo! Finance

The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Alkermes in Action: A Bed for Every Child
27 Sep, 2021 Yahoo! Finance

This summer, Alkermes continued its annual "Alkermes in Action" volunteer program, which offers employees opportunities to support local communities with hands-on activities that align with the com...

Alkermes to Take Part in the Cantor Virtual Global Healthcare Conference
22 Sep, 2021 Yahoo! Finance

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, Sept. 29, 2021 at 8:40 a.m. ET (1:40 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

New Survey Provides Insights Into Drinking Behaviors During the Pandemic
22 Sep, 2021 FinancialContent
Alkermes Earns Composite Rating Upgrade With An RS Line At New Highs
22 Sep, 2021 Yahoo! Finance

Alkermes saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 94 to 96. The upgrade means the stock is now outperforming 96% of all other stocks in terms of key performance metrics and technical strength. Alkermes stock is currently extended beyond a proper buy zone after clearing the 23.08 buy point in a cup with handle.

Alkermes Earns Composite Rating Upgrade
22 Sep, 2021 FinancialContent

Alkermes saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 94 to 96.

Recovery Month Renews Focus on Diagnosis, Treatment of Substance Use Disorder
21 Sep, 2021 FinancialContent
Interesting ALKS Put And Call Options For May 2022
17 Sep, 2021 FinancialContent

Investors in Alkermes plc (ALKS) saw new options become available this week, for the May 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Alkermes Associate Director Discusses How Her Personal Journey With Ovarian Cancer Influences Her Work
15 Sep, 2021 FinancialContent
Noteworthy Tuesday Option Activity: ALKS, PYPL, LRCX
14 Sep, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Alkermes plc (ALKS), where a total volume of 9,593 contracts has been traded thus far today, a contract volume which is representative of approximately 959,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 73.8% of ALKS's average daily trading volume over the past month, of 1.3 million shares..

Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program
13 Sep, 2021 FinancialContent
Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress
13 Sep, 2021 Yahoo! Finance

Alkermes plc (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress, taking place Sept. 16-21, 2021. The presentations will include a trial-in-progress poster for ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of nemvaleukin monotherapy in p

Benzinga's Bulls And Bears Of The Week: Alibaba, Apple, Nio, PayPal, Verizon And More
04 Sep, 2021 FinancialContent

Benzinga has examined the prospects for many investor favorite stocks over the past week. Last week's ...

Alkermes to Take Part in the Citi Annual BioPharma Virtual Conference
02 Sep, 2021 Yahoo! Finance

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Citi 16th Annual BioPharma Virtual Conference on Thursday, Sept. 9, 2021 at 8:50 a.m. ET (1:50 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

BofA Downgrades Alkermes After Stock Rally: 'We Don't See A Favorable Catalyst Pathway'
02 Sep, 2021 FinancialContent

Following the recent rally, Alkermes Plc’s (NASDAQ: ALKS) shares have exceeded their fair value and the stock looks ...

Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021
02 Sep, 2021 FinancialContent

Upgrades For Okta Inc (NASDAQ:OKTA), Needham upgraded the previous rating of Hold to Buy. In the second quarter, Okta ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
02 Sep, 2021 FinancialContent

Gainers Plus Therapeutics (NASDAQ:PSTV) shares increased by 22.1% to $2.32 during Thursday's pre-market session. The ...

Alkermes' (ALKS) Drug Portfolio Aids Growth, High Reliance a Woe
01 Sep, 2021 Yahoo! Finance

Alkermes' (ALKS) portfolio of proprietary products drives growth while its pipeline progress has been impressive. However, heavy dependence on partners for royalty revenues remains a concern.

Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
01 Sep, 2021 Yahoo! Finance

The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone, a potential treatment for schizophrenia.

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
01 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Alkermes Sr. Director of Oncology Discusses Career, Inspirational Women in STEM
31 Aug, 2021 FinancialContent

Alkermes plc (ALKS) is a NASDAQ Common Stock listed in , ,

970x250